Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Primes New Push Via Cipla For Avastin, Actemra In India

Executive Summary

Yesteryear rivals Roche and Cipla have sewn up a partnership under which Cipla will market a second brand of the Swiss giant’s Avastin (bevacizumab) and the IL-6 inhibitor, tocilizumab (Actemra), in India as they seek to expand access in a competitive, predominantly out-of-pocket market.

Related Content

Deal Watch: Celgene Makes Alliances With Kyn, Obsidian After Bristol Buyout
Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board
Roche To Set Right Avastin Post-Marketing Surveillance Delay In India
Home Gains Buoy Cipla In Q1 But US Momentum Pivotal
Deal Watch, Focus On Asia: Cipla Licenses India Rights To Lilly’s Basalgar
Roche India Mandate 'Completely Different' Says New Head Bezzera
Deal Watch: Roivant Adds Ligand's Glucose Receptor Antagonist To Metavant Pipeline
Biocon’s Avastin Biosimilar To Put The Heat On Competition?
Cipla Cuts Down In-House Biosimilars Plans
Unlikely allies MSD, Cipla link to co-market Isentress in India


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts